Back to BlackRock, Inc. BlackRock, Inc.

PTGXPTGX
7 quarters

Position history for BlackRock, Inc.BlackRock, Inc.'s holdings in PROTAGONIST THERAPEUTICS INC

BlackRock, Inc. holds 10.3M shares of PTGX (PROTAGONIST THERAPEUTICS INC), worth $1.3B as of 2026-Q2. The position was increased (+5.4% shares). PTGX represents 0.0% of BlackRock, Inc.'s portfolio.

Current Value

$1.3B

Current Shares

10.3M

Total Value Change

+$882M

Total Shares Change

+423,220

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
10.3M
+5.4%
$1.3B0.0%$122.58
34
2026-Q1
Increased
9.8M
+0.7%
$1B0.0%$91.30
32
2025-Q4
Increased
9.7M
+3.3%
$848.6M0.0%$87.26
33
2025-Q3
Decreased
9.4M
-2.4%
$624.7M0.0%$65.14
0
2025-Q2
Decreased
9.6M
-1.1%
$532.3M0.0%$55.69
0
2025-Q1
Decreased
9.7M
-1.5%
$470.9M0.0%$48.88
0
2024-Q4
New
9.9M
-
$381.5M0.0%$38.51
43

Other major holders of PTGX: FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, UBS Group AG

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used